Biology
Neutrophil Extracellular Traps in Autoimmune Disease Pathogenesis
Quick fact
NETs are composed of DNA and antimicrobial proteins, and they can act as a source of self-antigens. In lupus, impaired clearance of NETs is linked to the production of anti-double-stranded DNA antibodies, a hallmark of the disease.
Why this is interesting
Your immune system's first responders—neutrophils—can cast deadly webs that, when gone wrong, may turn your own body into an enemy. How do these microscopic traps, designed to catch bacteria, become a trigger for autoimmune diseases?
Read the full explanation
Understanding Neutrophil Extracellular Traps in Autoimmune Disease Pathogenesis
Imagine your immune system as a police force. Neutrophils are the rapid-response units that arrive first at the scene of an infection. Instead of just engulfing bacteria, they can also release their own DNA and proteins to form a sticky web—a NET—that physically traps and kills pathogens. This process is called NETosis. Normally, NETs are beneficial: they confine microbes and prevent their spread. However, if NETs are overproduced or not properly cleaned up, they can become a problem. The DNA in NETs is ‘self’ DNA, and the proteins attached to it are also self-proteins. When NETs linger, the immune system may mistake these components for foreign invaders, especially if they are modified during inflammation. In many autoimmune diseases, like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), NETs are found in abundance at sites of inflammation. The immune system starts to produce antibodies against its own DNA and proteins, leading to chronic inflammation and tissue damage. Thus, NETs act as both a trigger and a source of autoantigens.
A deeper explanation
The exact mechanism by which NETs contribute to autoimmunity is still being studied, but several key processes are involved. First, during NETosis, neutrophils release a mix of DNA and granule proteins, including histones and antimicrobial peptides. These complexes are often modified by enzymes, such as peptidylarginine deiminase (PAD), which citrullinates arginine residues. Citrullinated proteins are not normally found in high levels in the body, so they can be recognized as foreign—creating neoepitopes. This triggers an immune response, generating antibodies like anti-citrullinated protein antibodies (ACPAs) seen in RA. Second, NETs can activate plasmacytoid dendritic cells (pDCs) via toll-like receptor 9 (TLR9), which recognizes DNA. This activation leads to the production of type I interferons (IFN-α/β). These interferons are potent immune stimulators and are elevated in lupus. They further enhance the immune response and cause more NET formation, creating a vicious cycle. Third, defective clearance of NETs is common in autoimmunity. In SLE, for example, the enzyme DNase1, which degrades DNA, may be less active, or the NETs are protected from degradation by factors like anti-dsDNA antibodies. As a result, NETs persist and expose self-antigens for longer, promoting the generation of autoantibodies. Finally, NETs also provide a scaffold for the activation of the complement system, which further amplifies inflammation and tissue damage. Understanding this mechanism is crucial for developing targeted therapies. Drugs that inhibit PAD, degrade NETs, or block the DNA sensing pathways are being explored as potential treatments for autoimmune diseases. Thus, NETs are not just bystanders but active participants in the pathogenesis of autoimmune diseases.